Mediolanum International Funds Ltd Has $19.90 Million Stock Position in Gilead Sciences, Inc. $GILD

Mediolanum International Funds Ltd increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 84.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 179,832 shares of the biopharmaceutical company’s stock after buying an additional 82,402 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Gilead Sciences were worth $19,902,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. White Pine Capital LLC grew its position in shares of Gilead Sciences by 22.2% in the 2nd quarter. White Pine Capital LLC now owns 2,940 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 535 shares during the period. MAI Capital Management boosted its holdings in shares of Gilead Sciences by 12.4% in the second quarter. MAI Capital Management now owns 28,665 shares of the biopharmaceutical company’s stock valued at $3,178,000 after buying an additional 3,152 shares during the period. DNB Asset Management AS increased its position in shares of Gilead Sciences by 26.9% during the second quarter. DNB Asset Management AS now owns 289,340 shares of the biopharmaceutical company’s stock worth $32,079,000 after acquiring an additional 61,277 shares in the last quarter. Magnetar Financial LLC bought a new stake in shares of Gilead Sciences during the second quarter worth $2,582,000. Finally, Swiss National Bank raised its holdings in shares of Gilead Sciences by 7.4% during the second quarter. Swiss National Bank now owns 3,773,700 shares of the biopharmaceutical company’s stock worth $418,390,000 after acquiring an additional 258,700 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $124.99 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a 50 day moving average price of $118.23 and a 200 day moving average price of $113.37. The stock has a market capitalization of $155.07 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $88.07 and a 52 week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on GILD shares. Truist Financial reaffirmed a “buy” rating and issued a $145.00 target price (up from $127.00) on shares of Gilead Sciences in a research note on Monday, November 3rd. Wells Fargo & Company upped their price objective on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Finally, Needham & Company LLC upped their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $130.45.

Insiders Place Their Bets

In related news, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the transaction, the chief financial officer directly owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. This trade represents a 1.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 125,146 shares of company stock worth $15,148,441 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.